Development and Validation of a Decision-Making Stratification Algorithm to Optimize the Use of Rapid Diagnostic Testing for Patients with Staphylococcus Bacteremia
Affiliation
Univ Arizona, Coll Pharm, Dept Pharm Practice & SciIssue Date
2017
Metadata
Show full item recordPublisher
HINDAWI LTDCitation
Development and Validation of a Decision-Making Stratification Algorithm to Optimize the Use of Rapid Diagnostic Testing for Patients with Staphylococcus Bacteremia 2017, 2017:1 Canadian Journal of Infectious Diseases and Medical MicrobiologyRights
Copyright © 2017 Thamer A. Almangour et al. This is an open access article distributed under the Creative Commons Attribution License.Collection Information
This item from the UA Faculty Publications collection is made available by the University of Arizona with support from the University of Arizona Libraries. If you have questions, please contact us at repository@u.library.arizona.edu.Abstract
Purpose. To evaluate whether introducing rapid diagnostic testing in conjunction with implementing a stratification algorithm for testing eligibilitywould be an appropriate clinical and cost saving approach. Method. An internal concurrent 4-month observational study was performed. Positive blood cultures continued to be worked up in accordance with standard of care. An additional call to the infectious disease (ID) pharmacy service occurred for all positive blood cultures with Gram-positive cocci in clusters (GPCC). The ID pharmacy service investigated each case using a prespecified stratification algorithm to minimize unnecessary use of rapid identification testing. Results. 43 patients with GPCC were screened. Only nine patients met inclusion criteria for QuickFISH (TM) testing. The average expected time avoided to optimize antibiotic therapy is 35 perpendicular to 16 hours. If the QuickFISH test had been indiscriminately implemented for all cases, the cost for performing this test would have been $5,590. However, using the prespecified algorithm, only 9 patients were tested for a projected cost of $1,170. Conclusion. Introducing rapid diagnostic testing in conjunction with implementing patient stratification algorithm for rapid identification of GPCC from blood cultures in addition to the ID pharmacy intervention will provide a positive impact on the clinical and economic outcomes in our health care setting.Note
Open access journalISSN
1712-95321918-1493
Version
Final published versionAdditional Links
https://www.hindawi.com/journals/cjidmm/2017/8648137/ae974a485f413a2113503eed53cd6c53
10.1155/2017/8648137
Scopus Count
Collections
Except where otherwise noted, this item's license is described as Copyright © 2017 Thamer A. Almangour et al. This is an open access article distributed under the Creative Commons Attribution License.

